Published in Pharmacoepidemiol Drug Saf on July 01, 2004
Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol (2012) 1.40
Pharmacy students' knowledge and perceptions about pharmacovigilance in Malaysian public universities. Am J Pharm Educ (2011) 1.28
Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol (2012) 1.13
What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association. BMC Clin Pharmacol (2011) 1.13
Paediatric drug use with focus on off-label prescriptions at Swedish hospitals - a nationwide study. Acta Paediatr (2012) 1.03
Adverse drug reaction reporting by nurses in Sweden. Eur J Clin Pharmacol (2007) 1.03
A small economic inducement to stimulate increased reporting of adverse drug reactions--a way of dealing with an old problem? Eur J Clin Pharmacol (2006) 0.95
Individual case safety reports in children in commonly used drug groups - signal detection. BMC Clin Pharmacol (2008) 0.93
Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions. Br J Clin Pharmacol (2006) 0.89
Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. Eur J Clin Pharmacol (2009) 0.87
Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor. Eur J Clin Pharmacol (2007) 0.85
Attitudes among healthcare professionals to the reporting of adverse drug reactions in Nepal. BMC Pharmacol Toxicol (2013) 0.84
Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital. Br J Clin Pharmacol (2006) 0.83
Awareness among nurses about reporting of adverse drug reactions in Sweden. Drug Healthc Patient Saf (2012) 0.82
Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority. Eur J Clin Pharmacol (2012) 0.82
A prospective analysis of the preventability of adverse drug reactions reported in Sweden. Eur J Clin Pharmacol (2012) 0.82
Computerized techniques pave the way for drug-drug interaction prediction and interpretation. Bioimpacts (2016) 0.79
The promotion of data sharing in pharmacoepidemiology. Eur J Health Law (2014) 0.79
A systemic review of toxic death in clinical oncology trials: an Achilles' heel in safety reporting revisited. Br J Cancer (2012) 0.79
Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. Expert Opin Drug Saf (2016) 0.78
Life-threatening dermatologic adverse events in oncology. Anticancer Drugs (2014) 0.78
Sodium oxybate post-marketing surveillance. J Clin Sleep Med (2011) 0.76
Adverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and Reporting. PLoS One (2016) 0.75
Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan. Springerplus (2016) 0.75
Information and feedback to improve occupational physicians' reporting of occupational diseases: a randomised controlled trial. Int Arch Occup Environ Health (2009) 0.75
Severe hepatotoxic adverse reaction in a healthy schoolgirl after treatment with flucloxacillin. Drug Healthc Patient Saf (2009) 0.75
Clinical coding of prospectively identified paediatric adverse drug reactions--a retrospective review of patient records. BMC Pharmacol Toxicol (2014) 0.75
Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. Drug Saf (2017) 0.75
Public awareness and perception toward Adverse Drug Reactions reporting in Riyadh, Saudi Arabia. Saudi Pharm J (2017) 0.75
Attitudes to reporting adverse drug reactions in northern Sweden. Eur J Clin Pharmacol (2000) 1.72
HMG-CoA reductase inhibitors and myotoxicity. Drug Saf (2000) 1.51
Platelet serotonin 5-HT2A receptor binding in patients with carcinoid tumor. Scand J Clin Lab Invest (2004) 1.37
Comparison of theophylline and theobromine metabolism in man. Drug Metab Dispos (1986) 1.32
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Evaluation of a computer-based decision support system for treatment of hypertension with drugs: retrospective, nonintervention testing of cost and guideline adherence. J Intern Med (2000) 1.21
Nonlinear metabolic disposition of theophylline. Ther Drug Monit (1984) 1.16
Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry (1998) 1.10
Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine. J Clin Psychopharmacol (2001) 1.08
Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol (1988) 1.03
Adverse drug reaction reporting by nurses in Sweden. Eur J Clin Pharmacol (2007) 1.03
Spontaneous reporting of adverse drug reactions by nurses. Pharmacoepidemiol Drug Saf (2002) 0.98
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol (2003) 0.98
The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol (1990) 0.98
Pharmacokinetic properties of a new sustained-release theophylline preparation. Int J Clin Pharmacol Ther Toxicol (1983) 0.95
A small economic inducement to stimulate increased reporting of adverse drug reactions--a way of dealing with an old problem? Eur J Clin Pharmacol (2006) 0.95
Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin Pharmacol Ther (1988) 0.93
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol (2001) 0.92
Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther (1995) 0.91
The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics (1999) 0.90
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol (1997) 0.90
Adrenaline, emotional arousal and memory. Scand J Psychol (1985) 0.89
Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. Eur J Respir Dis (1982) 0.87
Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry (2001) 0.87
Effect of quinidine on plasma concentration and renal clearance of digoxin. A clinically important drug interaction. Br J Clin Pharmacol (1980) 0.86
DMSA administration to patients with alleged mercury poisoning from dental amalgams: a placebo-controlled study. J Dent Res (1994) 0.86
Serotonin syndrome caused by a moclobemide-clomipramine interaction. BMJ (1993) 0.86
Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol (1981) 0.85
Theophylline in maintenance treatment of chronic asthma: concentration-dependent additional effect to beta 2-agonist therapy. Eur J Respir Dis (1987) 0.85
Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. Eur J Clin Pharmacol (1999) 0.85
Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism. Clin Pharmacol Ther (1984) 0.84
Decreased density of serotonin 5-HT2A receptors in rheumatoid arthritis. Ann Rheum Dis (2006) 0.83
[Dicycloverin chloride solution--a remedy for severe infantile colic]. Lakartidningen (1983) 0.82
Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther (1990) 0.82
Serotonin 5-HT2A receptor binding in platelets from healthy subjects as studied by [3H]-lysergic acid diethylamide ([3H]-LSD): intra- and interindividual variability. Neuropsychopharmacology (1997) 0.82
Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists. J Clin Rheumatol (2004) 0.82
Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest (1987) 0.81
Changes in psychopathology in relation to EEG variables and visual averaged evoked responses (V.AER) in schizophrenic patients treated with penfluridol or thiothixene. Acta Psychiatr Scand (1977) 0.80
Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol (1999) 0.80
Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther (1991) 0.80
Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol (2000) 0.79
[Thrombosis caused by oracl contraceptives. Underreporting to the adverse effects registry]. Lakartidningen (1996) 0.79
Incorrect use and limited weight reduction of orlistat (Xenical) in clinical practice. A cohort study. Eur J Clin Pharmacol (2001) 0.78
A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol (1990) 0.78
Non-linear fluvoxamine disposition. Br J Clin Pharmacol (1998) 0.78
[Unnecessary work of the research ethics committees? A lot of work is done with studies which are never to be published]. Lakartidningen (2000) 0.77
Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand (1997) 0.77
Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol (2001) 0.77
Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance. Eur J Clin Pharmacol (1992) 0.77
The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol (2001) 0.76
Effect of fluvoxamine on platelet 5-HT2A receptors as studied by [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy volunteers. Psychopharmacology (Berl) (1997) 0.76
Penfluridol and thiothixene. Dosage, plasma levels and changes in psychopathology. Int Pharmacopsychiatry (1976) 0.76
Serotonin 5-HT2A receptor binding in platelets from patients with Alzheimer's disease or vascular dementia. Int Psychogeriatr (2000) 0.76
Alteration of dopamine receptors in the caudate nucleus and the putamen in schizophrenic brain. Med Biol (1986) 0.76
Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology (2001) 0.76
Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug reactions to sodium-aurothiomalate or d-penicillamine. Scand J Rheumatol (1987) 0.76
Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol (2001) 0.76
Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiol Drug Saf (2002) 0.76
[Calcitonin as medication in pain?]. Nord Med (1993) 0.75
No effect of probenecid on the renal and biliary clearances of digoxin in man. Br J Clin Pharmacol (1991) 0.75
Co-ordinating editor's comments on the letter to the editors by A. Herxheimer. Eur J Clin Pharmacol (2000) 0.75
Platelet [3H]paroxetine and [3H]lysergic acid diethylamide binding in seasonal affective disorder and the effect of bright light therapy. Biol Psychiatry (1999) 0.75
Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2000) 0.75
Circannual variations in the binding of [3H]lysergic acid diethylamide to serotonin2A receptors and of [3H]paroxetine to serotonin uptake sites in platelets from healthy volunteers. Biol Psychiatry (1998) 0.75
Cardiac effects of treatment with quinidine and digoxin, alone and in combination. Am J Cardiol (1983) 0.75
Biochemical and behavioural effects of thiothixene: relation to tissue levels of the drug. Acta Pharmacol Toxicol (Copenh) (1976) 0.75
Effects of cyanide on the striatal dopamine receptor binding in the rat. Eur J Pharmacol (1993) 0.75
Drug prescription patterns for rheumatic disorders in Sweden. J Rheumatol (1984) 0.75
Acetylator phenotypes in primary Sjögren's syndrome. Br J Rheumatol (1994) 0.75
Catechol-o-methyltransferase and plasma monoamine oxidase in patients with affective disorders. Acta Psychiatr Scand Suppl (1974) 0.75
Management of vitamin B12 deficiency in outpatient care. Scand J Prim Health Care (1993) 0.75
Theophylline--plasma concentration related to bronchodilatation and side effects. Prax Klin Pneumol (1983) 0.75
Plasma levels and protein binding of phenytoin during exercise in man: the effect of elevated free fatty acids. Pharmacology (1978) 0.75
Neurologic oral manifestations caused by a new formulation of mirtazapine. Neurology (2005) 0.75
[A regional center for reporting adverse drug reactions in Umeå. Prompt handling results in quick feedback]. Lakartidningen (1995) 0.75
Simultaneous treatment with terbutaline and theophylline. Eur J Respir Dis Suppl (1984) 0.75
[Monoamine oxidase (MAO) and catechol methyltransferase (COMT) in affective disturbances]. Nord Psykiatr Tidsskr (1972) 0.75
The relation between spiperone binding, behavioural changes, and in vivo tyrosine hydroxylation in the rat striatum. Naunyn Schmiedebergs Arch Pharmacol (1983) 0.75
Increased glucose intolerance related to digoxin treatment in patients with type 2 diabetes mellitus. J Intern Med (1999) 0.75
Plasma levels of chlorprothixene in alcoholics. Acta Psychiatr Scand Suppl (1974) 0.75
Renal function and digoxin clearance during quinidine therapy. Clin Physiol (1982) 0.75
Carbamazepine interference in a high-performance liquid chromatography analysis for perphenazine. Ther Drug Monit (1994) 0.75
Low serum sodium concentrations during treatment with citalopram in elderly patients: relationship to serum citalopram levels and to platelet serotonin 5-HT2A receptor status. J Clin Psychopharmacol (2000) 0.75
Concentration in plasma of an orally long-acting new neuroleptic, penfluridol. Acta Psychiatr Scand Suppl (1974) 0.75
[How important is following the physician's instructions? Demands on patients vary among different individual groups]. Lakartidningen (1993) 0.75
Interaction between the Drug Information Centre and the Regional Centre for Adverse Drug Reaction Monitoring in northern Sweden. Pharm World Sci (1997) 0.75
Chloroquine in long-term treatment of rheumatoid arthritis. Clin Rheumatol (1983) 0.75
Binding of [(3)H]lysergic acid diethylamide to serotonin 5-HT(2A) receptors and of [(3)H]paroxetine to serotonin uptake sites in platelets from healthy children, adolescents and adults. Neuropsychobiology (1999) 0.75
Digoxin-quinidine interaction. N Engl J Med (1979) 0.75
Clinical pharmacological evaluation of an assay kit for intoxications with tricyclic antidepressants. Ther Drug Monit (1986) 0.75
Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. Evidence for reduced binding of digoxin in muscle. N Engl J Med (1981) 0.75
Psychological versus physiological determinants of emotional arousal and its relationship to laboratory induced amnesia. Scand J Psychol (1986) 0.75